Table 3.
Demographic data of patients following HTx
| Control (n = 30) | Post-HTx (n = 85) | p-value* | No CAV (n = 62) | CAV (n = 23) | p-value† | |
|---|---|---|---|---|---|---|
| Galectin-3 (ng/ml) | 13.2 ± 9 | 17.8 ± 7 | 0.002 | 16.8 ± 6 | 20.5 ± 9 | 0.03 |
| Age (yrs) | 52 ± 8 | 55 ± 14 | NS | 54 ± 14 | 58 ± 13 | NS |
| Gender (% male) | 73 % | 71 % | NS | 80 % | 81 % | 0.02 |
| BMI (kg/m2) | 27 ± 5 | 29 ± 6 | NS | 29 ± 6 | 28 ± 5 | NS |
| Etiology (%) | ||||||
| Ischemic | - | 32 % | - | 54 % | 45 % | NS |
| Dilated | - | 43 % | 31 % | 45 % | ||
| Hypertrophy | - | 2 % | 0 % | 3 % | ||
| Unspecified | - | 13 % | 15 % | 7 % | ||
| LVEF (%) | - | 59 ± 8 | 60 ± 8 | 55 ± 8 | <0.0001 | |
| Years post-HTx | - | 5.4 ± 0.6 | - | 5.2 ± 1.2 | 5.5 ± 1.0 | NS |
| Comorbidities | ||||||
| Hypertension | 13.3 % | 61.7 % | <0.0001 | 55.6 % | 67.7 % | NS |
| Prior MIa | 0 % | 32.6 % | 0.0003 | 25.9 % | 45.2 % | NS |
| Hyperlipidemia | 23.3 % | 48.3 % | 0.02 | 50.0 % | 45.2 % | NS |
| Diabetes | 0 % | 49.4 % | <0.0001 | 50.0 % | 41.9 % | NS |
| Kidney Disease | 0 % | 38.2 % | <0.0001 | 31.5 % | 48.4 % | NS |
| COPDb | 0 % | 6.7 % | NS | 7.4 % | 3.2 % | NS |
| Smoker | 6.7 % | 5.6 % | NS | 7.4 % | 3.2 % | NS |
| Lab Values | ||||||
| WBCc (x103/μL) | 7.6 ± 5 | 6.8 ± 2.3 | NS | 6.9 ± 2.2 | 6.6 ± 2.6 | NS |
| Nad (mEq/L) | 145 ± 10 | 139 ± 2 | <0.0001 | 139 ± 2 | 140 ± 2 | NS |
| Creae (mg/dL) | 1.0 ± 0.3 | 1.5 ± 0.6 | <0.0001 | 1.5 ± 0.5 | 1.7 ± 0.6 | NS |
| T-Bilig (mg/dL) | 0.5 ± 0.2 | 0.7 ± 0.4 | 0.01 | 0.7 ± 0.3 | 0.8 ± 0.4 | NS |
| Albumin (g/dL) | 4.9 ± 0.4 | 4.3 ± 0.4 | <0.0001 | 4.3 ± 0.4 | 4.2 ± 0.5 | 0.05 |
*p value versus controls; †p value versus no CAV
a MI myocardial infarction, b COPD chronic obstructive pulmonary disease, c WBC white blood count, e Na sodium, f Crea creatinine; g T-Bili total bilirubi006E